Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer

NCT01957436 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT01957436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01957436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 13, 2013
Completion date
December 31, 2032
Enrollment
1,173 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer